Dental laser maker BIOLASE Technology (BLTI) has inked a sales and marketing pact with Kirkland, Washington-based leading dental education group Seattle Study Club (“SSC”).
SSC, a global organization of dentists, is among the most advanced dental education groups. Dentists and dental specialists, who are the members of the group, are dedicated to maintaining the highest level of knowledge in dentistry and share new techniques/technology and means to better serve their patients.
Under the agreement, BIOLASE will gain access to SSC’s 8,000 members and over 350 study clubs globally to educate them on how to make the best use of the company’s products and services.
The program will involve a number of activities including the demonstration of BIOLASE’s laser technology at SSC’s national symposiums, advertising in SSC publications, cooperative web marketing and direct promotions to members through SSC’s newsletters, webcasts and journal. The partnership is among a series of new marketing initiatives which BIOLASE plans to introduce this year.
BIOLASE develops and markets lasers and related products for applications in medicine and dentistry. Its key products are dental laser systems that perform a broad spectrum of dental procedures, including cosmetic and complex surgical applications.
The company’s sales more than doubled year over year in third-quarter 2011 to $13.1 million. The healthy growth was mainly attributable to its exit from an exclusive distribution arrangement with Henry Schein (HSIC) and return to a direct sales and multi-distributor model.
The company’s WaterLase all-tissue dental lasers accounted for roughly 63% of total sales in the quarter with the Waterlase iPlus laser contributing the most. BIOLASE, during the third quarter, won regulatory approvals in Canada and Russia to market the WaterLase iPlus laser.
Moreover, the company clinched regulatory approval for the device in South Korea in November 2011. Waterlase iPlus was launched in the U.S. in early 2011.
To read this article on Zacks.com click here.
Zacks Investment Research
